|
Epidemiology
| |
|
Age, y, mean ± SD
|
31 ± 8
|
|
Female gender, n (%)
|
20 (100)
|
|
Previous SLE manifestations
| |
|
Skin, n (%)
|
11 (55)
|
|
Joints, n (%)
|
9 (45)
|
|
Serositis, n (%)
|
4 (20)
|
|
Kidney, n (%)
|
11 (55)
|
|
Central nervous system, n (%)
|
1 (5)
|
|
SELENA-SLEDAI at Day 0, mean (range)
|
2 (0 to 8)
|
|
25-Hydroxyvitamin D levels
| |
|
Mean ± SD, ng/mL
|
22 ± 11
|
|
25(OH)D ≤ 10 ng/mL, n (%)
|
1 (5)
|
|
11 < 25(OH)D ≤ 20 ng/mL, n (%)
|
11 (55)
|
|
21 < 25(OH)D ≤ 30 ng/mL, n (%)
|
8 (40)
|
|
Associated treatments*
| |
|
Prednisone, n (%)
|
14 (70)
|
|
Prednisone, median, mg/day (range)
|
5 (0 to 15)
|
|
Hydroxychloroquine, n (%)
|
17 (85)
|
|
Azathioprine, n (%)
|
2 (10)
|
|
Mycophenolate mofetil, n (%)
|
1 (5)
|
